Frontlight ResearchEarly access
Taking people in South KoreaNo phase
Studies dapagliflozin in people with type 2 diabetes and high blood pressure
Observes how dapagliflozin works and its safety in adults with type 2 diabetes and hypertension.
Key facts
- Who runs it
- Boryung Pharmaceutical Co., Ltd
- Where
- Incheon, South KoreaSee the site
- Trial code
- Registry title
- A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
- Status
- Recruiting
- People taking part
- 9,000 people, planned
- Started
- 26 Jul 2023
- Planned end
- 21 Oct 2025
- Type of study
- Observational
- Record updated
- 15 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and high blood pressure who are about to start Trudapa Tab. or Trudapa M SR Tab. (dapagliflozin).
- Age
- 19 years and older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes mellitus together with hypertension (high blood pressure).
- Earlier treatment
- Must not have taken dapagliflozin within 4 weeks of baseline (Visit 1).
Main reasons for not taking part
- Secondary hypertension (high blood pressure caused by another disease)
- Took dapagliflozin within 4 weeks of baseline (Visit 1)
- Expected to need insulin during the study
- Pregnant or breast-feeding women
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab
- Those who voluntarily signed a written personal information agreement to participate in this clinical study
- Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion
Who cannot take part
- Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
- Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
- Those who are expected to need insulin prescription during the study period
- Pregnant women, breast-feeding women
Where in South Korea
- Gachon University Gil Medical CenterIncheon, South KoreaContact: Ki-young LeeTaking people
About the trial
What the trial wants to find out
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
- Plain-language title
- Studies dapagliflozin in people with type 2 diabetes and high blood pressureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 September 2025